SEC Info - Heron Therapeutics, Inc./DE

SEC Info℠

Home

Help

Please Sign In

Heron Therapeutics, Inc./DE – ‘8-K’ for 1/13/20

On: Monday, 1/13/20, at 8:41am ET · For: 1/13/20 · Accession #: 1564590-20-917 · File #: 1-33221

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/13/20  Heron Therapeutics, Inc./DE       8-K:2,7,9   1/13/20   12:27M                                    ActiveDisclosure/FA

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     33K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     30K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     57K 
12: R1          Document and Entity Information                     HTML     49K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 9: XML         XBRL Instance -- hrtx-8k_20200113_htm                XML     15K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.LAB  XBRL Labels -- hrtx-20200113_lab                     XML     58K 
 6: EX-101.PRE  XBRL Presentations -- hrtx-20200113_pre              XML     35K 
 4: EX-101.SCH  XBRL Schema -- hrtx-20200113                         XSD     19K 
 8: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    20K 
 7: ZIP         XBRL Zipped Folder -- 0001564590-20-000917-xbrl      Zip     30K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i HERON THERAPEUTICS, INC. /DE/ i 0000818033 0000818033 2020-01-13 2020-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i January 13, 2020

Heron Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

i Delaware

i 001-33221

i 94-2875566

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

i 4242 Campus Point Court, i Suite 200, i San Diego, i CA		i 92121
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code i (858) i 251-4400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, par value $0.01 per share		i HRTX		The i Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2020, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain of its financial results for the three and twelve months ended December 31, 2019 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.

This Item 2.02 and the Press Release attached hereto as Exhibit 99.1 are being furnished to the Securities and Exchange Commission.

Item 7.01 Regulation FD Disclosure.

Press Release.

On January 13, 2020, the Company issued the Press Release providing, among other things, a general update on corporate progress, as described in the Press Release.

Corporate Presentation.

A copy of presentation materials describing the business of the Company, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished herewith as Exhibit 99.2 (the “Corporate Presentation”). The Corporate Presentation has also been posted on the Company’s website at www.herontx.com. The Company does not undertake any obligation to update the Corporate Presentation.

This Item 7.01, the Press Release and the Corporate Presentation are being furnished to the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Press Release, dated January 13, 2020
99.2		Corporate Presentation, dated January 13, 2020
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Heron Therapeutics, Inc.

Date: January 13, 2020			/s/ *David Szekeres*
			David Szekeres Chief Legal, Business, and Administrative Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/13/20
	12/31/19	10-K, 5
		List all Filings

↑Top

Filing Submission 0001564590-20-000917 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)